68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The integration and transition of the brands are expected to be completed by June 2022.
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Perrigo expects to launch Omeprazole Minis later this year
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Subscribe To Our Newsletter & Stay Updated
